Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S
AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Mol Cancer Res. 2018 04; 16(4):720-727.
AR Expression in Breast Cancer CTCs Associates with Bone Metastases.
Nipp RD, Shui AM, Perez GK, Kirchhoff AC, Peppercorn JM, Moy B, Kuhlthau K, Park ER
Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act. JAMA Oncol. 2018 06 01; 4(6):791-797.
Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act.
TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer. 2007 Feb; 7(6):489-92.
TEACH: Tykerb evaluation after chemotherapy.
Jacobson BC, Moy B, Colditz GA, Fuchs CS
Postmenopausal hormone use and symptoms of gastroesophageal reflux. Arch Intern Med. 2008 Sep 08; 168(16):1798-804.
Postmenopausal hormone use and symptoms of gastroesophageal reflux.
Swan JS, Ying J, Stahl J, Kong CY, Moy B, Roy J, Halpern E
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing. Qual Life Res. 2010 Apr; 19(3):401-12.
Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing.
Post KE, Moy B, Furlani C, Strand E, Flanagan J, Peppercorn JM
Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer?. Clin J Oncol Nurs. 2017 Aug 01; 21(4):E99-E105.
Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer?.
Patient navigator programs, cancer disparities, and the patient protection and affordable care act. Oncologist. 2011; 16(7):926-9.
Patient navigator programs, cancer disparities, and the patient protection and affordable care act.
Lapatinib. Nat Rev Drug Discov. 2007 Jun; 6(6):431-2.
Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol. 2011 Oct 01; 29(28):3816-24.
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities.
Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur HL, Winer E, Norton L, Hudis CA, Dang CT
Clinical cancer research : an official journal of the American Association for Cancer Research
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 May 15; 17(10):3490-9.
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018 Dec; 172(3):733-740.
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
Winkfield KM, Phillips JK, Joffe S, Halpern MT, Wollins DS, Moy B
Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. J Clin Oncol. 2018 Sep 13; JCO1801132.
Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement.
Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007 Jul; 12(7):756-65.
Lapatinib-associated toxicity and practical management recommendations.
del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS
Mammographic breast density and race. AJR Am J Roentgenol. 2007 Apr; 188(4):1147-50.
Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L
The International journal of biological markers
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy. Int J Biol Markers. 2013 Apr 23; 28(1):17-23.
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.
Sepucha KR, Belkora JK, Chang Y, Cosenza C, Levin CA, Moy B, Partridge A, Lee CN
BMC medical informatics and decision making
Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery. BMC Med Inform Decis Mak. 2012 Jun 08; 12:51.
Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery.
Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM
Annals of oncology : official journal of the European Society for Medical Oncology
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol. 2019 04 01; 30(4):575-581.
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomaševic Z, Denduluri N, Šeparovic R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. Breast Cancer Res. 2019 03 11; 21(1):39.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Irwin KE, Moy B, Fields LE, Callaway CA, Park ER, Wirth L
Expanding Access to Cancer Clinical Trials for Patients With Mental Illness. J Clin Oncol. 2019 06 20; 37(18):1524-1528.
Expanding Access to Cancer Clinical Trials for Patients With Mental Illness.
Nipp RD, Lee H, Gorton E, Lichtenstein M, Kuchukhidze S, Park E, Chabner BA, Moy B
Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention. Oncologist. 2019 08; 24(8):1048-1055.
Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention.
Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol. 2019; 3:18.
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. Clin Cancer Res. 2019 11 01; 25(21):6443-6451.
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.
Sepucha KR, Langford AT, Belkora JK, Chang Y, Moy B, Partridge AH, Lee CN
Medical decision making : an international journal of the Society for Medical Decision Making
Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. Med Decis Making. 2019 08; 39(6):642-650.
Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients.
Freund KM, Haas JS, Lemon SC, Burns White K, Casanova N, Dominici LS, Erban JK, Freedman RA, James TA, Ko NY, LeClair AM, Moy B, Parsons SK, Battaglia TA
Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study. Cancer. 2019 12 15; 125(24):4532-4540.
Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study.
Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848.
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020 03 07; 395(10226):817-827.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
McCarthy AM, Kumar NP, He W, Regan S, Welch M, Moy B, Iafrate AJ, Chan AT, Bardia A, Armstrong K
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. BMC Cancer. 2020 Apr 23; 20(1):347.
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862.
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Spring LM, Specht MC, Jimenez RB, Isakoff SJ, Wang GX, Ly A, Shin JA, Bardia A, Moy B
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med. 2020 Jul 16; 383(3):262-272.
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With = 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020 09 20; 38(27):3138-3149.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With = 2 HER2-Directed Regimens: Phase III NALA Trial.
Smith BL, Nguyen A, Korotkin JE, Kelly BN, Specht MC, Spring LM, Moy B, Isakoff SJ, Gadd MA
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. Breast Cancer Res Treat. 2020 Oct; 183(3):515-524.
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
McDonough AL, Lei Y, Kwak AH, Haggett DE, Jimenez RB, Johnston KT, Moy B, Spring LM, Peppercorn J
Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. Clin Breast Cancer. 2021 02; 21(1):e88-e95.
Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors.
Yang DD, Buscariollo DL, Cronin AM, Weng S, Hughes ME, Bleicher RJ, Cohen AL, Javid SH, Edge SB, Moy B, Niland JC, Wolff AC, Hassett MJ, Punglia RS
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. Radiat Oncol. 2020 Aug 17; 15(1):198.
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer.
Beyerlin K, Jimenez R, Zangardi M, Fell GG, Edmonds C, Johnson A, Bossuyt V, Specht M, Mulvey TM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Spring LM
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. J Oncol Pharm Pract. 2021 Dec; 27(8):1883-1890.
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer. 2021 02; 21(1):80-91.e7.
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A
Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3404-3413.
Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer.
Asad S, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland J, Wolff AC, Hassett MJ, Stover DG
Journal of the National Comprehensive Cancer Network : JNCCN
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. J Natl Compr Canc Netw. 2021 03 10; 19(7):797-804.
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study.
Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R, Chan N
Neratinib?+?capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and?=?2 prior HER2-directed regimens. Breast Cancer Res Treat. 2021 Jul; 188(2):449-458.
Neratinib?+?capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and?=?2 prior HER2-directed regimens.
Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarcón J, Kalmadi S, Cronemberger E, Souza C, Landeiro L, Bose R, Bebchuk J, Kabbinavar F, Bryce R, Keyvanjah K, Brufsky AM
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Oncologist. 2021 08; 26(8):e1327-e1338.
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, Rugo H, Moy B, Bardia A
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist. 2021 10; 26(10):827-834.
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3938-3958.
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, Abraham E, Juric D, Isakoff SJ, Mayer E, Moy B, Supko JG, Tolaney SM, Bardia A
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Aug 04; 7(1):103.
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Disparities in phase 1 cancer clinical trial enrollment. Cancer. 2021 Dec 01; 127(23):4464-4469.
Disparities in phase 1 cancer clinical trial enrollment.
Saura C, Matito J, Oliveira M, Wildiers H, Brufksy AM, Waters SH, Hurvitz SA, Moy B, Kim SB, Gradishar WJ, Queiroz GS, Cronemberger E, Wallweber GJ, Bebchuk J, Keyvanjah K, Lalani AS, Bryce R, Vivancos A, Eli LD, Delaloge S
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clin Cancer Res. 2021 11 01; 27(21):5818-5827.
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
Antibody drug conjugates for patients with breast cancer. Curr Probl Cancer. 2021 10; 45(5):100795.
Antibody drug conjugates for patients with breast cancer.
LeClair AM, Battaglia TA, Casanova NL, Haas JS, Freund KM, Moy B, Parsons SK, Ko NY, Ross J, Ohrenberger E, Mullikin KR, Lemon SC
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Assessment of patient navigation programs for breast cancer patients across the city of Boston. Support Care Cancer. 2022 Mar; 30(3):2435-2443.
Assessment of patient navigation programs for breast cancer patients across the city of Boston.
Velimirovic M, Juric D, Niemierko A, Spring L, Vidula N, Wander SA, Medford A, Parikh A, Malvarosa G, Yuen M, Corcoran R, Moy B, Isakoff SJ, Ellisen LW, Iafrate A, Chabner B, Bardia A
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov; 4:1246-1262.
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer.
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol. 2022 03 01; 40(7):787-800.
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
Greer JA, Moy B, El-Jawahri A, Jackson VA, Kamdar M, Jacobsen J, Lindvall C, Shin JA, Rinaldi S, Carlson HA, Sousa A, Gallagher ER, Li Z, Moran S, Ruddy M, Anand MV, Carp JE, Temel JS
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer. J Natl Compr Canc Netw. 2022 02; 20(2):136-143.
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer.
Irwin KE, Ko N, Walsh EP, Decker V, Arrillaga-Romany I, Plotkin SR, Franas J, Gorton E, Moy B
Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care. Oncologist. 2022 07 05; 27(7):518-524.
Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.
O'Donnell E, Shapiro Y, Comander A, Isakoff S, Moy B, Spring L, Wander S, Kuter I, Shin J, Specht M, Kournioti C, Hu B, Sullivan C, Winters L, Horick N, Peppercorn J
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). Breast Cancer Res Treat. 2022 Jun; 193(3):579-587.
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast).
Sella T, Exman P, Ren S, Freret TS, Economy KE, Chen WY, Parsons HA, Lin NU, Moy B, Tung NM, Partridge AH, Tayob N, Mayer EL
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis. Breast Cancer Res Treat. 2022 Aug; 194(3):597-606.
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis.
Journal of the National Cancer Institute. Monographs
Enhancing Health Equity Through Cancer Health Economics Research. J Natl Cancer Inst Monogr. 2022 07 05; 2022(59):74-78.
Enhancing Health Equity Through Cancer Health Economics Research.
Perni S, Azoba C, Gorton E, Park ER, Chabner BA, Moy B, Nipp RD
Financial Toxicity, Symptom Burden, Illness Perceptions, and Communication Confidence in Cancer Clinical Trial Participants. JCO Oncol Pract. 2022 09; 18(9):e1427-e1437.
Financial Toxicity, Symptom Burden, Illness Perceptions, and Communication Confidence in Cancer Clinical Trial Participants.
Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 09 20; 40(27):3205-3221.
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
Hendrix N, Oestreicher N, Lalla D, Dolan CM, Fisher KA, Veenstra DL, Moy B
Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clin Breast Cancer. 2022 12; 22(8):781-791.
Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model.
Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022 09 10; 40(26):3088-3090.
Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
Denault E, Nakajima E, Naranbhai V, Hutchinson JA, Mortensen L, Neihoff E, Barabell C, Comander A, Juric D, Kuter I, Mulvey T, Peppercorn J, Rosenstock AS, Shin J, Vidula N, Wander SA, Moy B, Ellisen LW, Isakoff SJ, Iafrate AJ, Gainor JF, Bardia A, Spring LM
Therapeutic advances in medical oncology
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221119370.
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.
Shuman AG, Aapro MS, Anderson B, Arbour K, Barata PC, Bardia A, Bruera E, Chabner BA, Chen H, Choy E, Conte P, Curigliano G, Dizon D, O'Reilly E, Tito Fojo A, Gelderblom H, Graubert TA, Gurtler JS, Hall E, Hirsch FR, Idbaih A, Ilson DH, Kelley M, La Vecchia C, Ludwig H, Moy B, Muss H, Opdam F, Pentz RD, Posner MR, Ross JS, Sacher A, Senan S, Perez de Celis ES, Tanabe KK, Vermorken JB, Wehrenberg-Klee E, Bates SE
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization. Oncologist. 2022 Aug 13.
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization.
McCarthy AM, Manning AK, Hsu S, Welch M, Moy B, Lehman CD, Armstrong K
Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer. Breast Cancer Res Treat. 2022 Nov; 196(2):389-398.
Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer.
Sedrak MS, Sun CL, Ji J, Cohen HJ, Gross CP, Tew WP, Klepin HD, Wildes TM, Dotan E, Freedman RA, O'Connor T, Chow S, Fenton MA, Moy B, Chapman AE, Dale W, Katheria V, Kuderer NM, Lyman GH, Magnuson A, Muss HB
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. J Clin Oncol. 2023 01 10; 41(2):316-326.
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2023 02 20; 41(6):1318-1320.
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
McLaughlin S, Nakajima E, Bar Y, Hutchinson JA, Shin J, Moy B, Isakoff SJ, Bardia A, Kuter I, Spring LM
Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. Ther Adv Med Oncol. 2023; 15:17588359221146133.
Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer.
Abraham A, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland JC, Wolff AC, Hassett MJ, Asad S, Stover DG
Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. Breast. 2023 Feb; 67:89-93.
Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study.
Medford AJ, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, Dai CS, Gogakos T, Keenan JC, Occhiogrosso RH, Ryan P, Lennerz JK, Spring LM, Moy B, Ellisen LW, Bardia A
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis. Ther Adv Med Oncol. 2023; 15:17588359231152844.
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 03; 24(3):273-285.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnant M, Buyse M, Barrios CH, Silovski T, Šeparovic R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW, Loibl S, Masuda N, Tomaševic Z, Petráková K, DiPrimeo D, Wong A, Martin M, Chan A
European journal of cancer (Oxford, England : 1990)
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial. Eur J Cancer. 2023 05; 184:48-59.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, Che D, Nayar U, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Han HS, Iafrate AJ, Ryan LY, Juric D, Moy B, Ellisen LW, Maheswaran S, Wagle N, Haber DA, Bardia A, Wander SA
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO Precis Oncol. 2023 05; 7:e2200532.
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
Moy B, Wolff AC, Rumble RB, Allison KH, Carey LA
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2023 08; 19(8):547-550.
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
Vidula N, Niemierko A, Hesler K, Ryan L, Moy B, Isakoff S, Ellisen L, Juric D, Bardia A
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. NPJ Breast Cancer. 2023 Apr 19; 9(1):29.
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer.
Medford AJ, Moy B, Spring LM, Hurvitz SA, Turner NC, Bardia A
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clin Cancer Res. 2023 11 14; 29(22):4540-4548.
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.
Isakoff SJ, Said MR, Kwak AH, Glieberman E, O'Rourke EA, Stroiney A, Spring LM, Moy B, Bardia A, Horick N, Peppercorn JM
Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study). Breast Cancer Res Treat. 2023 Jun; 199(3):501-509.
Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study).
Medford AJ, Denault EN, Moy B, Parsons HA, Bardia A
Circulating Tumor DNA in Breast Cancer: Current and Future Applications. Clin Breast Cancer. 2023 10; 23(7):687-692.
Circulating Tumor DNA in Breast Cancer: Current and Future Applications.
Perez GK, Oberoi AR, Finkelstein-Fox L, Park ER, Nipp RD, Moy B
Cancer control : journal of the Moffitt Cancer Center
Qualitative study of Oncology Clinicians' Perceptions of Barriers to Offering Clinical Trials to Underserved Populations. Cancer Control. 2023 Jan-Dec; 30:10732748231187829.
Qualitative study of Oncology Clinicians' Perceptions of Barriers to Offering Clinical Trials to Underserved Populations.
Spring LM, Mortensen L, Abraham E, Keenan J, Medford A, Ma A, Padden S, Denault E, Ryan L, Iafrate AJ, Lennerz J, Hochberg E, Wander SA, Moy B, Isakoff SJ, Juric D, Brennan KA, Smith DE, Civiello B, Mulvey T, Comander A, Ellisen LW, Schwartz JH, Bardia A
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration. JCO Oncol Pract. 2024 01; 20(1):69-76.
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community Collaboration.
Ji J, Bae M, Sun CL, Wildes TM, Freedman RA, Magnuson A, O'Connor T, Moy B, Klepin HD, Chapman AE, Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Gross CP, Cohen HJ, Muss HB, Sedrak MS
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial. Cancer. 2024 03 15; 130(6):936-946.
Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.
Hantel A, Spence R, Camacho P, Bradbury AR, Denburg AE, Jagsi R, Moy B, Rathmell WK, Rosenberg AR, Symington B, Marron JM, Peppercorn J
ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. J Clin Oncol. 2024 Jan 20; 42(3):358-365.
ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages.
Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024 Mar; 35(3):293-301.
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2024 01; 10:e2300285.
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
Bone-Modifying Agents in Early Breast Cancer: Making Sense of Conflicting Data. NEJM Evid. 2022 Dec; 1(12):EVIDe2200259.
Bone-Modifying Agents in Early Breast Cancer: Making Sense of Conflicting Data.
Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, Partridge A, Juric D, Peppercorn J, Parsons H, Wander SA, Attaya V, Lormil B, Shellock M, Nagayama A, Bossuyt V, Isakoff SJ, Tolaney SM, Ellisen LW
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clin Cancer Res. 2024 Jul 15; 30(14):2917-2924.
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
Sedrak MS, Sun CL, Bae M, Freedman RA, Magnuson A, O'Connor T, Moy B, Wildes TM, Klepin HD, Chapman AE, Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Muss HB, Cohen HJ, Gross CP, Ji J
Journal of cancer survivorship : research and practice
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study. J Cancer Surviv. 2024 Aug; 18(4):1131-1143.
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study.
Freedman RA, Heiling HM, Li T, Trapani D, Tayob N, Smith KL, Davis R, Pereslete AM, DeMeo MK, Cotter C, Chen WY, Parsons HA, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Ashai N, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Rimawi MF, Krop IE, Lin NU
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024 Nov; 35(11):993-1002.
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022.
May FP, Brodney S, Tuan JJ, Syngal S, Chan AT, Glenn B, Johnson G, Chang Y, Drew DA, Moy B, Rodriguez NJ, Warner ET, Anyane-Yeboa A, Ukaegbu C, Davis AQ, Schoolcraft K, Regan S, Yoguez N, Kuney S, Le Beaux K, Jeffries C, Lee ET, Bhat R, Haas JS
Community Collaboration to Advance Racial/Ethnic Equity in Colorectal Cancer Screening: Protocol for a Multilevel Intervention to Improve Screening and Follow-up in Community Health Centers. Contemp Clin Trials. 2024 Oct; 145:107639.
Community Collaboration to Advance Racial/Ethnic Equity in Colorectal Cancer Screening: Protocol for a Multilevel Intervention to Improve Screening and Follow-up in Community Health Centers.
Moy B, Bradbury AR, Helft PR, Egleston BL, Sheikh-Salah M, Peppercorn J
Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol. 2013 Jul 20; 31(21):2678-84.
Correlation between financial relationships with commercial interests and research prominence at an oncology meeting.
Cancer health disparities and the cost of cancer care: payment model issues. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):633-6.
Cancer health disparities and the cost of cancer care: payment model issues.
The cost of cancer care--balancing our duties to patients versus society: are they mutually exclusive? Oncologist. 2013; 18(4):347-9.
The cost of cancer care--balancing our duties to patients versus society: are they mutually exclusive?
Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations. JCO Oncol Pract. 2024 Nov; 20(11):1515-1522.
Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations.
Spring LM, Scarpetti L, Medford AJ, Niemierko A, Comander A, Mulvey T, Schnipper L, Isakoff SJ, Moy B, Wander SA, Shin J, Ephrem Z, Laposta AR, Denault E, Abraham E, Calistro G, Kalashnikova E, Rodriguez A, Liu MC, Aleshin A, Peppercorn J, Ellisen LW, Bardia A
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER). NPJ Breast Cancer. 2025 Jan 07; 11(1):2.
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, Bitman E, Thant W, Liu T, Weipert C, Fell G, Spring LM, Wander SA, Moy B, Vidula N, Isakoff SJ, Varkaris A, Juric D, Corcoran RB, Ellisen LW, Bardia A
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2025 May 15; 31(10):1966-1974.
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Sood R, Niemierko A, Ryan L, Spring L, Moy B, Bardia A, Vidula N
Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer. Clin Cancer Res. 2025 Apr 01; 31(7):1315-1322.
Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer.
Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, Wander SA, Bardia A, Ko N, Moy B, Ellisen LW, Isakoff SJ
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. NPJ Breast Cancer. 2025 Mar 11; 11(1):27.
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.
Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ
Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. Biomed Opt Express. 2013; 4(12):2911-24.
Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system.
Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B
Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist. 2014 Feb; 19(2):186-92.
Ethical considerations for the clinical oncologist in an era of oncology drug shortages.
Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist. 2014 Apr; 19(4):348-9.
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Massachusetts general hospital: improving patient access to the breast oncology clinic. J Natl Compr Canc Netw. 2014 Feb; 12 Suppl 1:S25-7.
Massachusetts general hospital: improving patient access to the breast oncology clinic.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist. 2014 Apr; 19(4):346-7.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Value of cancer care: ethical considerations for the practicing oncologist. Am Soc Clin Oncol Educ Book. 2014; e146-9.
Value of cancer care: ethical considerations for the practicing oncologist.
Core elements of the patient protection and affordable care act and their relevance to the delivery of high-quality cancer care. Am Soc Clin Oncol Educ Book. 2012; e4-8.
Core elements of the patient protection and affordable care act and their relevance to the delivery of high-quality cancer care.
Bar Y, Wang GX, Gioia GE, Fell G, Chou SS, Bossuyt V, Isakoff SJ, Moy B, Ellisen LW, Lehman CD, Spring LM
Selection biases in the systematic collection of breast biobank specimens. NPJ Breast Cancer. 2025 Aug 01; 11(1):83.
Selection biases in the systematic collection of breast biobank specimens.
Post KE, Dunderdale L, Datta S, Varella L, Horick N, Traeger L, Greer JA, Moy B, Temel JS, Jacobs JM
Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study. Breast Cancer Res Treat. 2025 Nov 21; 215(1):7.
Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study.
Post KE, Dunderdale L, Datta S, Gutierrez N, Varella L, Horick N, Traeger L, Greer JA, Moy B, Temel JS, Jacobs JM
European journal of oncology nursing : the official journal of European Oncology Nursing Society
Development and refinement of a nurse-led, culturally sensitive intervention for adjuvant endocrine therapy initiation among patients with breast cancer. Eur J Oncol Nurs. 2025 Dec; 79:103010.
Development and refinement of a nurse-led, culturally sensitive intervention for adjuvant endocrine therapy initiation among patients with breast cancer.
McLaughlin S, Ravani LV, Moy B, Medford AJ, Isakoff SJ, Liu T, Ellisen LW, Spring LM, Wander SA, Abelman RO
Current landscape of sequencing ADCs in metastatic breast cancer. Ther Adv Med Oncol. 2025; 17:17588359251396656.
Current landscape of sequencing ADCs in metastatic breast cancer.
Solfisburg QS, Vang S, Foster V, Kwon SC, Moy B, Ko NY
Guidance for Community Engagement With Underserved Populations in Cancer Care. JCO Oncol Pract. 2026 Jan 28; OP2501127.
Guidance for Community Engagement With Underserved Populations in Cancer Care.
Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012 Oct 01; 14(5):R129.
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC
Geriatric oncology for the 21st century: a call for action. J Oncol Pract. 2014 Jul; 10(4):241-3.
Geriatric oncology for the 21st century: a call for action.
Lee CN, Wetschler MH, Chang Y, Belkora JK, Moy B, Partridge A, Sepucha KR
Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy. BMC Med Inform Decis Mak. 2014 Aug 20; 14:73.
Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 Oct 10; 32(29):3307-29.
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Debating the oncologist's role in defining the value of cancer care: our duty is to our patients. J Clin Oncol. 2014 Dec 20; 32(36):4039-41.
Debating the oncologist's role in defining the value of cancer care: our duty is to our patients.
Polite BN, Griggs JJ, Moy B, Lathan C, duPont NC, Villani G, Wong SL, Halpern MT
American Society of Clinical Oncology policy statement on medicaid reform. J Clin Oncol. 2014 Dec 20; 32(36):4162-7.
American Society of Clinical Oncology policy statement on medicaid reform.
Moy B, Specht MC, Lanuti M, Rafferty EA, Lerwill MF
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy. N Engl J Med. 2015 Jan 08; 372(2):162-70.
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Recognizing the Financial Burden of Cancer Patients in Clinical Trials. Oncologist. 2015 Jun; 20(6):572-5.
Recognizing the Financial Burden of Cancer Patients in Clinical Trials.
Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015 Apr; 51(6):685-96.
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene. Oncologist. 2015 Jun; 20(6):571.
Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene.
Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb 01; 33(4):340-8.
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015 Apr 16; 17:56.
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
The impact of industry on oncology research and practice. Am Soc Clin Oncol Educ Book. 2015; 130-7.
The impact of industry on oncology research and practice.
Moy BC, Prairie MD, Krueger WC, Bhuyan BK
Interaction of CC-1065 and its analogues with mouse DNA and chromatin. Cancer Res. 1989 Apr 15; 49(8):1983-8.
Interaction of CC-1065 and its analogues with mouse DNA and chromatin.
Moy BC, Petzold GL, Badiner GJ, Kelly RC, Aristoff PA, Adams EG, Li LH, Bhuyan BK
Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184. Cancer Res. 1990 Apr 15; 50(8):2485-92.
Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184.
Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, Blitzblau RC, Moy B, Breslin T, Edge SB, Hassett MJ, Punglia RS
International journal of radiation oncology, biology, physics
Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):622-30.
Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A
Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol. 2015 Nov 01; 33(31):3621-7.
Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
Announcing a New Journal Section: Community Outreach. Oncologist. 2016 Jan; 21(1):1.
Announcing a New Journal Section: Community Outreach.
Badiner GJ, Moy BC, Smith KS, Tarpley WG, Groppi VE, Bhuyan BK
P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype. Br J Cancer. 1990 Sep; 62(3):378-84.
P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.
Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016 Mar; 56:85-92.
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers.
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar; 17(3):367-377.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Nipp RD, Lee H, Powell E, Birrer NE, Poles E, Finkelstein D, Winkfield K, Percac-Lima S, Chabner B, Moy B
Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. Oncologist. 2016 Apr; 21(4):467-74.
Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.
Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. Am Soc Clin Oncol Educ Book. 2016; 35:e22-9.
Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications.
Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA
Journal of the National Cancer Institute
Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. J Natl Cancer Inst. 2016 12; 108(12).
Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.
Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1477-1486.
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting? Oncologist. 2016 12; 21(12):1411-1413.
The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?
No Conflict, No Interest. JAMA Oncol. 2016 Dec 01; 2(12):1631-1632.
Moy B, Tu D, Shepherd LE, Pater JL, Whelan TJ, Ingle JN, Goss PE
NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6018.
NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women.
Moy B, Rappold E, Williams L, Kelly T, Nicolodi L, Maltzman JD, Goss PE
Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol. 2009 May 20; 27(15_suppl):1043.
Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib.
Carp SA, Wanyo C, Specht MC, Schapira L, Moy B, Finkelstein DM, Boas D, Isakoff SJ
Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. J Clin Oncol. 2011 Sep 20; 29(27_suppl):60.
Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer.
Goss PE, Barrios CH, Chan A, Chia SK, Delaloge S, Ejlertsen B, Ingle JN, Moy B, Iwata H, Holmes FA, Mansi J, Von Minckwitz G, Han L, Thiele A, Agrapart V, Freyman A, Truscello J, Berkenblit A, Finkelstein D
A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS137.
A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).
Chow L, Xu B, Dirix LY, Moy B, Leip E, Bardy-Bouxin N, Duvillie L, Sarosiek T
Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC). J Clin Oncol. 2011 May 20; 29(15_suppl):614.
Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC).
Carp SA, Wanyo C, Specht M, Schapira L, Moy B, Finkelstein D, Boas D, Isakoff SJ
Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):10607.
Moy B, Lebrun F, Bellet M, Chow L, Lang I, Xu B, Badwe RA, Hershman DL, Leip E, Bardy-Bouxin N, Duvillie L, Neven P
Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC). J Clin Oncol. 2011 May 20; 29(15_suppl):631.
Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).
Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW
Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. J Clin Oncol. 2013 Sep 10; 31(26_suppl):145.
Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.
Morris PG, Patil S, Chen C, Abbruzzi A, Lehman RJ, Steingart R, Oeffinger KC, Lin NU, Moy B, Come SE, Winer EP, Norton L, Hudis C, Dang CT
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). J Clin Oncol. 2013 Sep 10; 31(26_suppl):167.
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Powell E, Finkelstein D, Winkfield KM, Percac-Lima S, Chabner BA, Moy B
Alleviating financial burden for cancer patients in clinical trials. J Clin Oncol. 2014 Oct 20; 32(30_suppl):10.
Alleviating financial burden for cancer patients in clinical trials.
Martin M, Von Minckwitz G, Ejlertsen B, Chia SK, Buyse ME, Mansi J, Gnant M, Holmes FA, Moy B, Iwata H, Wong A, Lalani AS, Bryce R, Bebchuk JD, Delaloge S
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. J Clin Oncol. 2015 Oct; 33(28_suppl):117.
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.
Hospitalizations and emergency department use in cancer clinical trial patients. J Clin Oncol. 2015 Oct 10; 33(29_suppl):160.
Hospitalizations and emergency department use in cancer clinical trial patients.
Palliative care consultation for patients enrolled in cancer clinical trials. J Clin Oncol. 2015 Oct 10; 33(29_suppl):139.
Palliative care consultation for patients enrolled in cancer clinical trials.
Cheng X, Bhatia A, Specht MC, Smith BL, Moy B, Bardia A
Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer. J Clin Oncol. 2013 Sep 10; 31(26_suppl):147.
Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.
Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA
Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). Biomed Opt Express. 2017 Feb 01; 8(2):555-569.
Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).
Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E
Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 May 24; 16(10).
Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017 06; 163(3):535-544.
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006 Aug 15; 12(16):4790-3.
Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
Ozanne EM, Partridge A, Moy B, Ellis KJ, Sepucha KR
Doctor-patient communication about advance directives in metastatic breast cancer. J Palliat Med. 2009 Jun; 12(6):547-53.
Doctor-patient communication about advance directives in metastatic breast cancer.
Lapatinib: current status and future directions in breast cancer. Oncologist. 2006 Nov-Dec; 11(10):1047-57.
Lapatinib: current status and future directions in breast cancer.
Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Jun 20; 35(18):2062-2081.
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 Oct; 16(10):895-903.
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Jan; 14(1):88-96.
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017 09; 22(9):1039-1048.
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Campbell EG, Moy B, Feibelmann S, Weissman JS, Blumenthal D
Institutional academic industry relationship: results of interviews with university leaders. Account Res. 2004 Apr-Jun; 11(2):103-18.
Institutional academic industry relationship: results of interviews with university leaders.
Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S, Goold SD
Institutional academic industry relationships. JAMA. 2007 Oct 17; 298(15):1779-86.
Institutional academic industry relationships.
Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8.
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Ethical challenges: caring for the underinsured, geographically disadvantaged patient. J Oncol Pract. 2012 Jul; 8(4):215-8.
Ethical challenges: caring for the underinsured, geographically disadvantaged patient.
Medical integrity up in smoke? Conflicts of interest and the lung cancer screening controversy. Oncologist. 2008 May; 13(5):474-6.
Medical integrity up in smoke? Conflicts of interest and the lung cancer screening controversy.
Lee CN, Chang Y, Adimorah N, Belkora JK, Moy B, Partridge AH, Ollila DW, Sepucha KR
Journal of the American College of Surgeons
Decision making about surgery for early-stage breast cancer. J Am Coll Surg. 2012 Jan; 214(1):1-10.
Decision making about surgery for early-stage breast cancer.
Moy B, Park ER, Feibelmann S, Chiang S, Weissman JS
Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women. Psychooncology. 2006 Jul; 15(7):623-34.
Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women.
Lee CN, Belkora J, Chang Y, Moy B, Partridge A, Sepucha K
Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article]. Plast Reconstr Surg. 2011 Jan; 127(1):18-26.
Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article].
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw. 2017 10; 15(10):1216-1223.
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary. J Oncol Pract. 2017 12; 13(12):822-824.
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol. 2017 Dec 10; 35(35):3978-3986.
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Blanchard K, Colbert JA, Puri D, Weissman J, Moy B, Kopans DB, Kaine EM, Moore RH, Halpern EF, Hughes KS, Tanabe KK, Smith BL, Michaelson JS
Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer. 2004 Aug 01; 101(3):495-507.
Mammographic screening: patterns of use and estimated impact on breast carcinoma survival.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomaševic Z, Denduluri N, Šeparovic R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 12; 18(12):1688-1700.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol. 2006 Nov; 17(11):1637-43.
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Sepucha KR, Ozanne EM, Partridge AH, Moy B
Is there a role for decision aids in advanced breast cancer? Med Decis Making. 2009 Jul-Aug; 29(4):475-82.
Is there a role for decision aids in advanced breast cancer?
Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Raj A, Ko N, Battaglia TA, Chabner BA, Moy B
Patient navigation for underserved patients diagnosed with breast cancer. Oncologist. 2012; 17(8):1027-31.
Patient navigation for underserved patients diagnosed with breast cancer.
Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med. 2000 May 08; 160(9):1370-2.
Hemolytic uremic syndrome associated with clopidogrel: a case report.